ATE237587T1 - 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten - Google Patents
11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthaltenInfo
- Publication number
- ATE237587T1 ATE237587T1 AT98901576T AT98901576T ATE237587T1 AT E237587 T1 ATE237587 T1 AT E237587T1 AT 98901576 T AT98901576 T AT 98901576T AT 98901576 T AT98901576 T AT 98901576T AT E237587 T1 ATE237587 T1 AT E237587T1
- Authority
- AT
- Austria
- Prior art keywords
- derivatives
- dialkylprostaglandin
- production
- active ingredients
- products containing
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 101150053131 PTGER3 gene Proteins 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4157197 | 1997-02-10 | ||
| PCT/JP1998/000544 WO1998034916A1 (fr) | 1997-02-10 | 1998-02-10 | Derives de 11,15-o-dialkylprostaglandine e, leur procede de production, et medicaments renfermant ceux-ci comme principe actif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE237587T1 true ATE237587T1 (de) | 2003-05-15 |
Family
ID=12612138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98901576T ATE237587T1 (de) | 1997-02-10 | 1998-02-10 | 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6288119B1 (de) |
| EP (1) | EP1008588B1 (de) |
| JP (1) | JP4044967B2 (de) |
| KR (1) | KR20000070903A (de) |
| AT (1) | ATE237587T1 (de) |
| DE (1) | DE69813571T2 (de) |
| DK (1) | DK1008588T3 (de) |
| ES (1) | ES2196527T3 (de) |
| PT (1) | PT1008588E (de) |
| WO (1) | WO1998034916A1 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体 |
| US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| WO2004032964A1 (ja) * | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | アレルギー性疾患治療剤 |
| EP2465537B1 (de) | 2002-10-10 | 2016-06-29 | ONO Pharmaceutical Co., Ltd. | Microkugeln enthaltend ONO-1301 |
| WO2004074842A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3) |
| WO2004089411A1 (ja) * | 2003-04-03 | 2004-10-21 | Ono Pharmaceutical Co., Ltd. | 脊柱管狭窄症治療剤 |
| WO2005009468A1 (ja) | 2003-07-25 | 2005-02-03 | Ono Pharmaceutical Co., Ltd. | 軟骨関連疾患治療剤 |
| EP1707208A4 (de) * | 2003-12-05 | 2010-03-17 | Ono Pharmaceutical Co | Blutflusspromotoren für cauda-equina-gewebe |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| MY145694A (en) * | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| BRPI0611079A2 (pt) | 2005-06-03 | 2010-08-03 | Ono Pharmaceutical Co | agentes para a regeneração e/ou proteção de nervos |
| CA2618486A1 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
| SI1976828T1 (sl) | 2005-12-29 | 2017-07-31 | Celtaxsys, Inc. | Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze |
| US8466188B2 (en) | 2006-10-12 | 2013-06-18 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| EP2076514A1 (de) * | 2006-10-12 | 2009-07-08 | Xenon Pharmaceuticals Inc. | SPIRO(FURO[3,2-C]PYRIDIN-3,3ý-INDOL)-2ý(1ýH)-ONDERIVATE UND VERWANDTE VERBINDUNGEN ZUR BEHANDLUNG VON DURCH NATRIUMKANÄLE VERMITTELTEN KRANKHEITEN WIE SCHMERZEN |
| EP2220057A4 (de) | 2007-11-14 | 2011-10-12 | Cayman Chem Co | Prostaglandin-e1- und e2-analoga zur behandlung verschiedener medizinischer leiden |
| US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| EP2942350A1 (de) | 2008-10-17 | 2015-11-11 | Xenon Pharmaceuticals Inc. | Spirooxindol-verbindungen und deren verwendungen als therapeutika |
| US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| RU2531350C2 (ru) | 2009-06-10 | 2014-10-20 | Оно Фармасьютикал Ко., Лтд. | Соединение, обладающее сокращающей детрузор активностью и релаксирующей уретральный сфинктер активностью |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| RU2015103694A (ru) | 2009-10-14 | 2015-06-27 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| PE20121699A1 (es) | 2010-02-26 | 2012-12-22 | Xenon Pharmaceuticals Inc | Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica |
| CN105753877A (zh) | 2012-04-12 | 2016-07-13 | 泽农医药公司 | 用作治疗剂的螺-羟吲哚化合物的不对称合成 |
| MX344385B (es) | 2012-08-31 | 2016-12-14 | Ono Pharmaceutical Co | Sal de amina y cristales de la misma. |
| RU2696559C2 (ru) | 2013-03-14 | 2019-08-05 | Селтакссис, Инк. | Ингибиторы лейкотриен а4-гидролазы |
| EP2818484A1 (de) | 2013-06-28 | 2014-12-31 | Universitat Autònoma de Barcelona | Synergistische Kombination eines Anti-IgE-Antikörpers und eines EP2-Rezeptoragonisten |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
| US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
| RU2019119652A (ru) | 2016-12-09 | 2021-01-11 | Селтакссис, Инк. | Ингибиторы лейкотриен-а4-гидролазы |
| EP3551608A1 (de) | 2016-12-09 | 2019-10-16 | Celtaxsys Inc. | Anhängende amine und derivate als inhibitoren der leukotrien-a4-hydrolase |
| US10385007B2 (en) | 2016-12-09 | 2019-08-20 | Celtaxsys, Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835180A (en) * | 1971-05-04 | 1974-09-10 | Upjohn Co | 15 alkoxy pge compounds |
| US3876690A (en) * | 1973-05-11 | 1975-04-08 | American Cyanamid Co | 1-alkoxy-9-keto-prostenoic acid derivatives |
| GB1451798A (en) * | 1973-08-02 | 1976-10-06 | Ici Ltd | Prostanoic acid derivatives |
| US4236027A (en) * | 1977-10-17 | 1980-11-25 | American Cyanamid Company | Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same |
| JPS55115836A (en) * | 1979-03-02 | 1980-09-06 | Toray Ind Inc | Preparation of methyl ether derivative |
| DE3510978A1 (de) * | 1985-03-22 | 1986-09-25 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPH03101622A (ja) * | 1989-09-11 | 1991-04-26 | Green Cross Corp:The | 肝炎予防治療剤 |
-
1998
- 1998-02-10 DE DE69813571T patent/DE69813571T2/de not_active Expired - Fee Related
- 1998-02-10 DK DK98901576T patent/DK1008588T3/da active
- 1998-02-10 US US09/355,626 patent/US6288119B1/en not_active Expired - Lifetime
- 1998-02-10 ES ES98901576T patent/ES2196527T3/es not_active Expired - Lifetime
- 1998-02-10 AT AT98901576T patent/ATE237587T1/de not_active IP Right Cessation
- 1998-02-10 EP EP98901576A patent/EP1008588B1/de not_active Expired - Lifetime
- 1998-02-10 JP JP53414898A patent/JP4044967B2/ja not_active Expired - Lifetime
- 1998-02-10 KR KR1019997007168A patent/KR20000070903A/ko not_active Application Discontinuation
- 1998-02-10 PT PT98901576T patent/PT1008588E/pt unknown
- 1998-02-10 WO PCT/JP1998/000544 patent/WO1998034916A1/ja not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1008588A4 (de) | 2000-06-14 |
| KR20000070903A (ko) | 2000-11-25 |
| JP4044967B2 (ja) | 2008-02-06 |
| ES2196527T3 (es) | 2003-12-16 |
| PT1008588E (pt) | 2003-09-30 |
| DE69813571T2 (de) | 2004-02-12 |
| WO1998034916A1 (fr) | 1998-08-13 |
| DK1008588T3 (da) | 2003-07-28 |
| DE69813571D1 (de) | 2003-05-22 |
| EP1008588A1 (de) | 2000-06-14 |
| US6288119B1 (en) | 2001-09-11 |
| EP1008588B1 (de) | 2003-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE237587T1 (de) | 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten | |
| MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
| ATE264337T1 (de) | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung | |
| CA2333703A1 (en) | Isothiazole derivatives useful as anticancer agents | |
| NL300175I2 (nl) | Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2. | |
| ATE321543T1 (de) | Pharmazeutische zusammensetzungen mit hydroximsäurederivaten | |
| MA26725A1 (fr) | Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation | |
| DE60225143D1 (de) | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes | |
| ATE19236T1 (de) | (omega-(diaethylamino)-alkoxy)-alpha-(aethyl)benzhydrolderivate, ihre saeureadditionssalze und quaternaeren salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
| DE60137442D1 (de) | 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung | |
| DE69600272D1 (de) | Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE50204789D1 (de) | Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| HUP9802897A2 (hu) | Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
| AU5879798A (en) | Agents inhibiting progress of pterygium and postoperative recurrence of the same | |
| HUP0004900A2 (hu) | Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények | |
| CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
| MXPA04003200A (es) | Nuevos compuestos de isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| ATE223717T1 (de) | Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen | |
| DK0805817T3 (da) | Thiolderivater med metallopeptidaseinhiberende aktivitet | |
| BR0109252A (pt) | Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição | |
| ATE178901T1 (de) | Anthracyclin-disaccharide, verfahren zu ihrer herstellung, und diese enthaltende arzneimittel | |
| ATE265459T1 (de) | Triazolpurin-derivate, medikamentzusammensetzungen, die diese enthalten und mittel, die affinität zum adenosin a3 rezeptor zeigen | |
| BR9915898A (pt) | Compostos, composição farmacêutica, e, utilização de um composto | |
| CA2267247A1 (fr) | Heteroaryloxyethylamines en tant que ligands 5-ht1a | |
| DK0823254T3 (da) | Hidtil ukendt anvendelse af pyrazolopyridinforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1008588 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |